Mon Health System and Intermed Labs Partnership Results in Successful Commercial Exit of Innovative Technology

Team Members at Intermed Labs at Mon Health

Intermed Labs at Mon Health has announced that a technology solution conceived by a Mon Health System physician has been acquired by a publicly traded company to support sacral neuromodulation (SNM). The acquisition of this novel technology marks a significant milestone in the partnership between Mon Health and Intermed Labs, which was formed to develop innovative technology to improve patient outcomes.

The technology created at Intermed Labs at Mon Health addresses SNM challenges with an elegant solution comprising a software application and a hardware tool that makes peripheral nerve evaluation (PNE) lead placement easier, faster, and more accurate.

Launched in 2020, Intermed Labs at Mon Health has opened the door to innovation for physicians, clinicians, and engineers to connect individuals who have ideas for improving patient outcomes with the expertise and resources needed to turn those ideas into real-world solutions.

“The partnership between Intermed Labs and Mon Health exemplifies the power of collaboration in bringing life-changing innovations to life. We are thrilled to see technology created by one of our own physicians being leveraged to drive progress and make a positive impact on patient care,” said David Goldberg, President and CEO of Mon Health System and Executive Vice President of Vandalia Health. “This acquisition confirms our strong, robust, and flourishing relationship with Intermed Labs that we will continue to foster.”

Intermed Labs at Mon Health is a first-of-its-kind medical technology startup studio that has created a pathway for transformational innovation and job creation in healthcare using development and commercialization strategies.

“Intermed Labs’ progress and success shows that West Virginia and a community healthcare system like Mon Health, with such talented colleagues, can innovate and create solutions for patients and commercialize. We are showing how we can move West Virginia forward,” Goldberg said.

Intermed Labs has gained international recognition, including the ECRI Health Devices Achievement Award, which presents its annual award to the facility that has carried out the most exceptional initiative to improve patient safety, reduce costs, or otherwise facilitate better strategic management of health technology. It was also awarded the Top Innovator of 2022 for the Fingy3D device during The Tank: Plastic Surgery Innovation Challenge hosted by the American Society of Plastic Surgeons, the world’s largest organization of board-certified plastic surgeons.

“Our collaboration has been extremely beneficial in creating indirect return on investment and building a culture of innovation here in West Virginia and beyond. This acquisition cements our position as the regional innovator in biomedical development,” said Dr. Tom McClellan, Co-Founder and CEO of Intermed Labs. “The technology, devices, and clinical solutions created through Intermed Labs at Mon Health has helped to improve patient outcomes, local economic benefit, and educational opportunities.”

The acquisition was completed for undisclosed terms. It is expected that the product will receive FDA clearance and be available on a commercial basis in mid-2024.

To learn more about Intermed Labs at Mon Health, visit IntermedLabs.com.